Through the collaboration, Genentech will use genome sequencing and survey data on Parkinson’s disease patients, and 23andMe will then be able to conduct additional research on the data.
“We are incredibly excited to work with Genentech again, and for the potential to make breakthroughs in therapeutic research and treatment for Parkinson’s disease,” said Andy Page, president of 23andMe. “This collaboration is truly emblematic of both companies’ broader vision of improving the human condition through genetic research.”
More articles on genomics:
IBM Watson-powered app to deliver personalized health info
IBM, Cleveland Clinic to use Watson for cancer genomics pilot
Phoenix Children’s Hospital opens pediatric genomic research & precision medicine institute
